Genetic medicines for multi-systemic treatment of inherited diseases including Cystinosis, Friedreich's ataxia, Danon disease, and Alzheimer's disease.HIGHLIGHT: Papillon's first indication targeting Cystinosis reported positive Ph1/2 data and is now licensed to Novartis.UPDATES: FDA granted both of Papillon's preclinical programs (PPL-001, PPL-002) designations for Orphan Drug (ODD) and Rare Pediatric Disease (RPD).

Cellular and genetic medicines to regenerate the heart, including induced pluripotent stem cell (iPSC) cardiomyocyte replacement therapy for treatment of heart failure.HIGHLIGHT: StemCardia licensed over 60 patents from University of Washington (UW) and entered a collaboration with a leading regenerative medicine center University of Southern California (USC).

Cellular and genetic medicines to regenerate the brain, including induced pluripotent stem cell (iPSC) dopamine neuron replacement for treatment for Parkinson's disease.HIGHLIGHT: $82 Million Series A Financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, with participation from Euclidean Capital and Saisei Ventures.

Cellular medicines to regenerate the retina, including induced pluripotent stem cell (iPSC) photoreceptor replacement for treatment of inherited primary photoreceptor disease and age-related macular degeneration (AMD).HIGHLIGHT: Opsis entered into a Strategic R&D Alliance with Bayer AG subsidiary, Blue Rock, including a $70 million up-front commitment.UPDATES: Option for OpCT-001 was exercised, and the IND for OpCT-001 received FDA clearance.

Cellular medicines to regenerate microvasculature, including induced pluripotent stem cell (iPSC) vascular progenitor replacement as treatment for critical limb threatening ischemia (CLTI/CLI).HIGHLIGHT: Vascugen has completed pre-IND with FDA and manufacture of its clinical grade (GMP) iPSC-derived vascular progenitor product in support of clinical development.

Inclusive clinical pharmacogenetic (PGx) testing, analysis, and reporting of actionable drug compatibility results to patients and leading healthcare providers across the US.HIGHLIGHT: RPRDx operates a dedicated CLIA-certified clinical diagnostic facility offering proprietary Psych HealthPGx Panel and Comprehensive CYP2C19 Test.

Developed mineral coated microparticle (MCM) platform technology for protein and RNA drugs with improved stability and controlled release.HIGHLIGHT: Entered into a $4 million partnership with Ligand Pharmaceuticals (LGND).

Foundry for disruptive biotech ventures with a focus on disease-modifying genetic medicines.

VC fund that combines Western expertise and Japanese innovation to build globally competitive companies that will have the greatest impact on patient lives.HIGHLIGHT: Sasei is one of only nine VC funds certified by the Japan Agency for Medical Research and Development (AMED), who provide matching investment from the Japanese government.